News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Subscribe

Spotlight -

Predictions for 2026: Our January 2026 issue|

MHE State of the Industry survey|

AMCP Nexus 2025|

2025 Fall Clinical Dermatology|

Opinion|Videos|August 14, 2024

Key Patient Factors Guiding Myelofibrosis Treatment Selection

Author(s)Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, outlines factors that inform treatment decisions for patients with myelofibrosis, including comorbidities and platelet count.

Episodes in this series

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 1 Myelofibrosis Overview: US Incidence, Prognosis, and Patient Presentation

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 2 Unmet Needs in Myelofibrosis: Key Challenges in Disease Management

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 3 Impact of Myelofibrosis on Quality of Life: Key Clinical Features

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 4 Primary Management Goals and Importance of Risk Stratification in Myelofibrosis

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 5 JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 6 Key Patient Factors Guiding Myelofibrosis Treatment Selection

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 7 Key Outcomes for Monitoring Myelofibrosis Treatment Response

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 8 Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 9 Understanding Financial Toxicity in Myelofibrosis

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, an expert on myelofibrosis

EP. 10 Advancing Myelofibrosis Treatment: What Lies Ahead

EP. 11 K-Cast Written Summary. Optimizing the Management of Myelofibrosis

EP. 11 K-Cast Written Summary. Optimizing the Management of Myelofibrosis

Video content above is prompted by the following question:

What are some specific patient factors that guide treatment selection in alignment with current NCCN guidelines?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Related Content

Key Takeaways for AD Management

ByMatthew Zirwas, M.D.

April 9th 2025

Integrating New AD Therapies Into Clinical Practice

ByMatthew Zirwas, M.D.

April 9th 2025

Recent Advancements in AD Treatment

ByMatthew Zirwas, M.D.

April 2nd 2025

Overcoming Barriers to Treatment in AD

ByMatthew Zirwas, M.D.

April 2nd 2025

Shared Decision-Making in AD Management

ByMatthew Zirwas, M.D.

March 26th 2025

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Huntington Beach Symposia

In-Person + Virtual Event

Huntington Beach Symposia

February 19-21, 2026

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Heather A. Wakelee, MD, FASCO

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Zofia Piotrowska, MD, MHS; Bruna Pellini, MD; Alice Shaw, MD, PhD

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Marina Chiara Garassino, MD; Sarah Goldberg, MD, MPH; Biagio Ricciuti, MD, PhD

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Jacob Sands, MD; Anne Chiang, MD, PhD; Alissa J. Cooper, MD

22nd Annual Winter Lung Cancer Conference®

22nd Annual Winter Lung Cancer Conference®

Julie Brahmer, MD; Rogerio C. Lilenbaum, MD, FACP, FASCO; Mark A. Socinski, MD

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Lauren Averett Byers, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

Trending on Managed Healthcare Executive

7 things you need to know about the PBM reforms signed into law this week

Cancer survival fell and deaths rose during first two years of COVID-19

FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals

TrumpRx launches; some experts question its long-term value

PBM reform. It has finally happened